Ftse Mib
34.456,38
-0,43%
DAX
18.680,20
-0,25%
S&P 500
5.318,75
-0,05%
NASDAQ
16.829,54
-0,02%
Bitcoin
70.255,80
0,18%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Acasti Pharma Inc (ACST) Acasti Pharma Inc (ACST) Notizie

ACST

Acasti Pharma (ACST)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACST
DataOraFonteTitoloSimboloCompagnia
10/05/202422:11Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ACSTAcasti Pharma Inc
09/05/202401:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACSTAcasti Pharma Inc
12/02/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACSTAcasti Pharma Inc
12/02/202413:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACSTAcasti Pharma Inc
08/01/202414:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACSTAcasti Pharma Inc
17/10/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACSTAcasti Pharma Inc
16/10/202322:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ACSTAcasti Pharma Inc
10/10/202313:40Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ACSTAcasti Pharma Inc
06/10/202322:30Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ACSTAcasti Pharma Inc
25/08/202323:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACSTAcasti Pharma Inc
25/08/202322:21Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACSTAcasti Pharma Inc
25/08/202322:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ACSTAcasti Pharma Inc
10/07/202315:00PR Newswire (US)Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH PatientsNASDAQ:ACSTAcasti Pharma Inc
07/07/202314:00PR Newswire (US)Acasti Pharma Announces 1-for-6 Reverse Stock SplitNASDAQ:ACSTAcasti Pharma Inc
05/07/202315:00PR Newswire (US)Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023NASDAQ:ACSTAcasti Pharma Inc
23/06/202313:02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ACSTAcasti Pharma Inc
23/06/202313:00PR Newswire (US)Acasti Pharma Reports Fiscal Year 2023 Operational ResultsNASDAQ:ACSTAcasti Pharma Inc
22/06/202315:00PR Newswire (US)Acasti Announces Appointment of New Scientific Advisory Board MembersNASDAQ:ACSTAcasti Pharma Inc
26/05/202321:07Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ACSTAcasti Pharma Inc
17/05/202315:00PR Newswire (US)Acasti to Participate in the Lytham Partners Spring 2023 Investor ConferenceNASDAQ:ACSTAcasti Pharma Inc
08/05/202313:00PR Newswire (US)Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025NASDAQ:ACSTAcasti Pharma Inc
05/04/202323:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACSTAcasti Pharma Inc
04/04/202314:01PR Newswire (US)Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the INDNASDAQ:ACSTAcasti Pharma Inc
04/04/202314:00PR Newswire (US)Acasti Announces Appointment of Prashant Kohli as CEONASDAQ:ACSTAcasti Pharma Inc
30/03/202314:30PR Newswire (US)Acasti Pharma Inc. Announces the Resignation of a DirectorNASDAQ:ACSTAcasti Pharma Inc
13/03/202313:00PR Newswire (US)Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture ExchangeNASDAQ:ACSTAcasti Pharma Inc
08/03/202315:00PR Newswire (US)Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare ConferenceNASDAQ:ACSTAcasti Pharma Inc
28/02/202319:00PR Newswire (US)Acasti Pharma Recognizes Rare Disease DayNASDAQ:ACSTAcasti Pharma Inc
14/02/202313:02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ACSTAcasti Pharma Inc
14/02/202313:00GlobeNewswire Inc.Acasti Pharma Reports Third Quarter 2023 Operational ResultsNASDAQ:ACSTAcasti Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACST

La tua Cronologia

BIT
UCG
Unicredit
BIT
STMMI
ST Microelectronics
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
SPM
Saipem
BIT
TIT
Telecom Italia
BIT
TEN
Tenaris
BIT
BPE
Bper Banca
BIT
LDO
Leonardo
BIT
RACE
Ferrari NV
BIT
G
Generali
BIT
SRG
Snam
BIT
BAMI
Banco BPM
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network